Subgroup analyses have often been highlighted as problematic, but the methods used and the interpretation of these analyses have remained substandard. Emphasis on the apparently positive results of ...

Of 882 participants enrolled, 128 had PD-L1 CPS < 1 and 373 had CPS 1-19. For pembrolizumab versus cetuximab-chemotherapy, the median overall survival was 7.9 versus 11.3 months in the PD-L1 CPS < 1 ...